Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Participants in clinical trials value personalized, accurate information about study results

Participants in clinical trials report being satisfied with personalized, accurate communication of results by study investigators soon after the study findings are released publicly, according to a report in the December issue of Archives of Neurology.

8 Dec 2008

Cambridge Labs announces Spanish approval of Tetrabenazine

Cambridge Laboratories Limited has announced that its flagship product Tetrabenazine, (known as NITOMAN in Germany and other key European territories and XENAZINE in the UK, U.S. and other markets) has received marketing approval in Spain from the Agencia Espanola de Medicamentos y Productos Sanitarios.

8 Dec 2008

Novel approach to disseminate trial results to study volunteers

While an estimated 2.3 million people in the U.S. take part in clinical trials every year, there currently exists no formal requirement to inform them of study results; an oversight that leaves participants confused, frustrated, and, in some cases, lacking information that may be important to their health.

8 Dec 2008

Defective calcium metabolism in nerve cells contributes to neurological disorder

Defective calcium metabolism in nerve cells may play a major role in a fatal genetic neurological disorder that resembles Huntington's disease, researchers at UT Southwestern Medical Center have found in a mouse study.

26 Nov 2008

Neuralstem enters stem cell collaboration for Huntington's disease in Germany

Neuralstem, Inc. announced today that it has entered into a collaboration with Professor Guido Nikkah Ph.D, of Albert-Ludwigs-University in Freiburg, Germany, to advance development of Neuralstem's human neural stem cell therapies.

18 Nov 2008

New clue for cellular damage in Huntington's disease

"Huntington's disease presents an ideal vantage point to study neurodegenerative disease, because we know the misfolded protein that's responsible," says Martin Duennwald, formerly a postdoctoral researcher in the lab of Whitehead Member Susan Lindquist.

16 Nov 2008

Breakthrough in cellular analysis

Like skilled assassins, many diseases seem to know exactly what types of cells to attack.

16 Nov 2008

Breakthrough in cell-type analysis offers new ways to study development and disease

Like skilled assassins, many diseases seem to know exactly what types of cells to attack. While decimating one cadre of cells, diseases will inexplicably spare a seemingly identical group of neighbors. What makes cells vulnerable or not depends largely on the kinds and amounts of proteins they produce - their 'translational profile,' in the lingo of molecular biology. For this reason, scientists have struggled to parse the subtle molecular differences among the hundreds of specialized cell types that are tangled together in tissues like the brain.

13 Nov 2008

Novel tool helps study the biochemical basis of Alzheimer's

A new study being published in this Friday's online edition of Cell will help answer the question, what causes Parkinson's disease?

12 Nov 2008

Dental pulp stem cells show promise for use in cell therapy

Researchers at the Yerkes National Primate Research Center, Emory University, have discovered dental pulp stem cells can stimulate growth and generation of several types of neural cells.

12 Nov 2008

Nicotinamide, a form of vitamin B3, reduces Alzheimer's symptoms

An over-the-counter vitamin in high doses prevented memory loss in mice with Alzheimer's disease, and UC Irvine scientists now are conducting a clinical trial to determine its effect in humans.

5 Nov 2008

Gene find sheds light on motor neuron diseases like amyotrophic lateral sclerosis

Scientists have identified a gene in mice that plays a central role in the proper development of one of the nerve cells that goes bad in amyotrophic lateral sclerosis, or Lou Gehrig's disease, and some other diseases that affect our motor neurons.

22 Oct 2008

First drug for Huntington's disease approved for use in the U.S.

Huntington's disease is a fatal, inherited neurodegenerative disorder for which there is no cure and usually affects people in their 30s and 40s, but some patients are affected as early as childhood, while others aren't affected until they are older.

18 Aug 2008

FDA approves tetrabenazine for Huntington's disease

The U.S. Food and Drug Administration has approved tetrabenazine, the first drug approved for use in the United States to treat Huntington's disease, a fatal, inherited neurodegenerative disorder for which there is no cure. The action comes about eight months after an advisory panel unanimously voted to advise FDA to make the medication available to treat the disease.

17 Aug 2008

Cannabinoid cell surface receptor plays a tumor-suppressing role in human colorectal cancer

CB1 is well-established for relieving pain and nausea, elevating mood and stimulating appetite by serving as a docking station for the cannabinoid group of signaling molecules. It now may serve as a new path for cancer prevention or treatment.

3 Aug 2008

New ways of exploiting medicinal uses of cannabis

Research exploring new ways of exploiting the full medicinal uses of cannabis while avoiding unwanted side-effects will be presented to pharmacologists Tuesday, 15 July by leading scientists attending the Federation of European Pharmacological Societies Congress, EPHAR 2008.

From The University of Manchester 15 Jul 2008

Huntington's disease brain damage linked to overactive immune response in the bloodstream

The damage to brain tissue seen in Huntington's disease may be caused by an overactive immune response in the bloodstream and the brain, according to new findings from two teams of researchers at the University of Washington in Seattle and University College London. The findings will be published online July 14 in the Journal of Experimental Medicine.

14 Jul 2008